Does avatrombopag (Sucoxin) affect liver function and how to monitor it

Avatrombopag is a new type of thrombopoietin receptor agonist (TPO-RA). It is mainly used to treat preoperative thrombocytopenia and chronic immune thrombocytopenic purpura (ITP) in patients with chronic liver disease. It reduces the risk of bleeding by stimulating megakaryocyte proliferation and differentiation and promoting platelet production. Since many users have abnormal liver function, "whether avatrombopag will affect liver function" has become an important issue of clinical concern. Overall studies show that the drug has a small direct effect on liver function, but individual differences still need to be noted.

From a pharmacological perspective, avatrombopag is mainly metabolized by the liver and relies on the CYP2C9 and CYP3A4 enzyme systems. Clinical studies have shown that in patients with chronic liver disease, the drug metabolism process is relatively stable and there is no significant hepatotoxicity. Most patients' liver function indicators (such as ALT, AST) remained normal or fluctuated only slightly during treatment. However, since the drug is mainly metabolized in the liver, patients with moderate to severe liver function impairment still need to use it with caution and monitor closely, and adjust the dose or extend the dosing interval if necessary.

Some individuals may experience mild liver enzyme elevations during treatment, but this is usually a reversible reaction and is related to underlying liver disease or combined medication factors. If patients take concomitant antiviral drugs, antifungal drugs, or other hepatotoxic drugs, the risk of abnormal liver function may increase. Therefore, clinicians generally recommend avoiding concurrent use of medications that may increase the burden on the liver during use of avatrombopag. In addition, patients should maintain a healthy diet and avoid drinking alcohol or high-fat foods to reduce metabolic stress on the liver.

In terms of monitoring, it is recommended that patients conduct baseline liver function tests before taking the drug, and regularly review ALT, AST and bilirubin levels during treatment. Especially those in the early stages of treatment or long-term drug users should increase the frequency of monitoring. Once symptoms such as obvious elevation of liver enzymes or jaundice occur, the drug should be discontinued promptly and evaluated. In general, avatrombopag has little impact on liver function when used rationally and under standardized monitoring, and is a relatively safe platelet-promoting drug. Scientific monitoring and individualized management can help patients achieve curative effects while reducing liver-related risks.

Reference materials:https://www.drugs.com/